February 21, 2017 / 3:26 PM / 10 months ago

BUZZ-EyeGate Pharmaceuticals Inc: Expands Valeant partnership

** Eye drug developer’s shares soar as much as 74.40 pct to $2.86; highest since Aug. 1

** Stock top pct gainer on Nasdaq

** Says it has given Valeant Pharmaceuticals International Inc commercial and manufacturing rights to the EyeGate’s drug delivery technology as well as for its experimental drug, EGP-437, for use in post-operative pain and inflammation in ocular surgery patients

** Partnership follows a 2015 agreement in which Valeant secured a license for EGP-437 to treat uveitis, a form of eye inflammation

** Valeant’s U.S.-listed shares rise about 1.6 pct to $16.30

** Up to Friday’s close, EyeGate’s stock had risen about 26 pct YTD

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below